{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:45:26Z","timestamp":1761709526731,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00373","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T03:55:37Z","timestamp":1536638137000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk"],"prefix":"10.3389","volume":"8","author":[{"given":"Michael C.","family":"Repka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lloyd","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeng","family":"Suy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Voyadzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Kalhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"McGrail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa S.","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Lischalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"volume-title":"Clinical Radiation Oncology","year":"2012","author":"Gunderson","key":"B1"},{"key":"B2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial","volume":"49","author":"Walker","year":"1978","journal-title":"J Neurosurg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"van den Bent","year":"2013","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00401-010-0781-z","article-title":"Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas","volume":"120","author":"Hartmann","year":"2010","journal-title":"Acta Neuropathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1756-8722-3-22","article-title":"CyberKnife enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures","volume":"3","author":"Oermann","year":"2010","journal-title":"J Hematol Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/neuonc\/nou349","article-title":"Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis","volume":"17","author":"Almenawer","year":"2015","journal-title":"Neuro Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3171\/jns.1987.66.6.0865","article-title":"Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms","volume":"66","author":"Kelly","year":"1987","journal-title":"J Neurosurg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","article-title":"A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma","volume":"5","author":"Westphal","year":"2003","journal-title":"Neuro Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/0360-3016(79)90553-4","article-title":"An analysis of dose-effect relationship in the radiotherapy of malignant gliomas","volume":"5","author":"Walker","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.2002.20.6.1635","article-title":"Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy","volume":"20","author":"Chan","year":"2002","journal-title":"J Clin Oncol"},{"key":"B21","unstructured":""},{"key":"B22","unstructured":""},{"key":"B23","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/0360-3016(89)90548-8","article-title":"Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations","volume":"17","author":"Halperin","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"vi133","DOI":"10.1093\/neuonc\/nos238","article-title":"To compare the treatment outcomes of two different target volume delineation guidelines (RTOG vs MD Anderson) in glioblastoma multiforme patients: a prospective randomized study","volume":"14","author":"Kumar","year":"2012","journal-title":"Neuro Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.radonc.2015.12.003","article-title":"ESTRO-ACROP guideline \u201ctarget delineation of glioblastomas","volume":"118","author":"Niyazi","year":"2016","journal-title":"Radiother Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00373\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T03:55:39Z","timestamp":1536638139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00373\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":27,"alternative-id":["10.3389\/fonc.2018.00373"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00373","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"article-number":"373"}}